Influence of drug loading and type of ointment base on the in vitro performance of acyclovir ophthalmic ointment

被引:34
作者
Al-Ghabeish, Manar [1 ]
Xu, Xiaoming [1 ]
Krishnaiah, Yellela S. R. [1 ]
Rahman, Ziyaur [1 ]
Yang, Yang [1 ]
Khan, Mansoor A. [1 ]
机构
[1] CDER OPQ OTR DPQR, Food & Drug Adm, Silver Spring, MD 20993 USA
关键词
Ophthalmic ointment; Performance tests; Acyclovir; Transcorneal permeation; Semisolid dosage form; Drug retention in cornea; Drug release; RABBIT CORNEA; HERPES-SIMPLEX; PERMEATION; RELEASE; TRANSPORTER; EPITHELIUM; MECHANISM; DELIVERY; OPTISOL; STORAGE;
D O I
10.1016/j.ijpharm.2015.08.096
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The availability of in vitro performance tests such as in vitro drug release testing (IVRT) and in vitro permeation testing (IVPT) are critical to comprehensively assure consistent delivery of the active component(s) from semisolid ophthalmic drug products. The objective was to study the impact of drug loading and type of ointment base on the in vitro performance (IVRT and IVPT) of ophthalmic ointments using acyclovir as a model drug candidate. The in vitro drug release for the ointments was evaluated using a modified USP apparatus 2 with Enhancer cells. The transcorneal permeation was carried out using rabbit cornea on modified vertical Franz cells. The drug retention in cornea (DRC) was also determined at the end of transcorneal drug permeation study. The in vitro drug release, transcorneal drug permeation as well as DRC exhibited a proportional increase with increasing drug loading in the ointment. On comparing the in vitro drug release profile with transcorneal permeation profile, it appears that drug release from the ointment is controlling acyclovir transport through the cornea. Furthermore, enhanced in vitro transcorneal permeation relative to the in vitro drug release underscores the importance of the interplay between the physiology of the ocular tissue and ointment formulation. The results indicated that IVRT and IVPT could be used to discriminate the impact of changes in drug load and formulation composition of ophthalmic ointments. (C) 2015 Published by Elsevier B.V.
引用
收藏
页码:783 / 791
页数:9
相关论文
共 38 条
  • [1] Mechanism of corneal permeation of L-valyl ester of acyclovir: Targeting the oligopeptide transporter on the rabbit cornea
    Anand, BS
    Mitra, AK
    [J]. PHARMACEUTICAL RESEARCH, 2002, 19 (08) : 1194 - 1202
  • [2] Ophthalmic Drug Dosage Forms: Characterisation and Research Methods
    Baranowski, Przemyslaw
    Karolewicz, Bozena
    Gajda, Maciej
    Pluta, Janusz
    [J]. SCIENTIFIC WORLD JOURNAL, 2014,
  • [3] ACYCLOVIR - A REVIEW OF THE PRE-CLINICAL AND EARLY CLINICAL-DATA OF A NEW ANTI-HERPES DRUG
    BRIGDEN, D
    FIDDIAN, P
    ROSLING, AE
    RAVENSCROFT, T
    [J]. ANTIVIRAL RESEARCH, 1981, 1 (04) : 203 - 212
  • [4] Calpena AC, 1999, ARZNEIMITTEL-FORSCH, V49, P1012
  • [5] ELION GB, 1993, J MED VIROL, P2
  • [6] FDA, 1997, NONST SEM DOS FORMS, VCMC 7, P19
  • [7] FDA, 2015, IN INGR SEARCH APPR
  • [8] Safety assessment on polyethylene glycols (PEGs) and their derivatives as used in cosmetic products
    Fruijtier-Pölloth, C
    [J]. TOXICOLOGY, 2005, 214 (1-2) : 1 - 38
  • [9] Improved and safe transcorneal delivery of flurbiprofen by NLC and NLC-based hydrogels
    Gonzalez-Mira, Elisabet
    Nikolic, Sasa
    Calpena, Ana C.
    Antonia Egea, M.
    Souto, Eliana B.
    Luisa Garcia, M.
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2012, 101 (02) : 707 - 725
  • [10] ACYCLOVIR (ZOVIRAX) OPHTHALMIC OINTMENT - A REVIEW OF CLINICAL TOLERANCE
    GRANT, DM
    [J]. CURRENT EYE RESEARCH, 1987, 6 (01) : 231 - 235